Step into our expansive academic footprint
Publications
Development of a drug screening platform based on engineered heart tissue
Hansen et al., Circ Res (2010), DOI: 10.1161/CIRCRESAHA.109.211458, PMID: 20448218
Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology
Schaaf et al., PLoS One (2011), DOI: 10.1371/journal.pone.0026397, PMID: 22028871
Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation
Hirt et al., J Mol Cell Cardiol (2014), DOI: 10.1016/j.yjmcc.2014.05.009, PMID: 24852842
Human engineered heart tissue as a model system for drug testing
Eder et al., Adv Drug Deliv Rev (2016), DOI: 10.1016/j.addr.2015.05.010, PMID: 26026976
Blinded contractility analysis in hiPSC-cardiomyocytes in engineered heart tissue format: comparison with human atrial trabeculae
Mannhardt et al., Toxicol Sci (2017), DOI: 10.1093/toxsci/kfx081, PMID: 28453742
Force and calcium transients analysis in human engineered heart tissues reveals positive force-frequency relation at physiological frequency
Saleem et al., Stem Cell Reports (2020), DOI: 10.1016/j.stemcr.2019.12.011, PMID: 31956082
Blinded, multicenter evaluation of drug-induced changes in contractility using human-induced pluripotent stem cell-derived cardiomyocytes
Saleem et al., Toxicol Sci (2020), DOI: 10.1093/toxsci/kfaa058, PMID: 32421822
Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue
Rhoden et al., Redox Biol (2021), DOI: 10.1016/j.redox.2021.101951, PMID: 33831709
Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations
Rhoden et al., Am J Physiol Heart Circ Physiol (2022), DOI: 10.1152/ajpheart.00534.2021, PMID: 35030072
Reproducibility of drug-induced effects on the contractility of an engineered heart tissue derived from human pluripotent stem cells
Arefin et al., Front Pharmacol (2023), DOI: 10.3389/fphar.2023.1212092, PMID: 37469866